Tocilizumab is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor, playing a significant role in the immune response and inflammation. It is primarily used in the treatment of autoimmune diseases such as rheumatoid arthritis and systemic juvenile idiopathic arthritis. Tocilizumab works by inhibiting IL-6 signaling, which is crucial in the pathogenesis of these conditions. The substance is administered via intravenous or subcutaneous injection, and its pharmacokinetics can vary based on the patient's characteristics and the disease being treated. Common side effects may include increased risk of infections, gastrointestinal perforations, and liver enzyme elevations. Tocilizumab has also gained attention for its potential use in treating severe cases of COVID-19 due to its anti-inflammatory properties. As a therapeutic agent, it is essential to monitor patients for adverse effects and to assess its efficacy in conjunction with other treatments. Overall, Tocilizumab represents a significant advancement in targeted therapies for inflammatory diseases.

Tocilizumab

375823-41-9: Tocilizumab is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor, playing a significant role in the immune response and inflammation. It is primarily used in the treatment of autoimmune diseases such as rheumatoid arthritis and systemic juvenile idiopathic arthritis. Tocilizumab works by inhibiting IL-6 signaling, which is crucial in the pathogenesis of these conditions. The substance is administered via intravenous or subcutaneous injection, and its pharmacokinetics can vary based on the patient's characteristics and the disease being treated. Common side effects may include increased risk of infections, gastrointestinal perforations, and liver enzyme elevations. Tocilizumab has also gained attention for its potential use in treating severe cases of COVID-19 due to its anti-inflammatory properties. As a therapeutic agent, it is essential to monitor patients for adverse effects and to assess its efficacy in conjunction with other treatments. Overall, Tocilizumab represents a significant advancement in targeted therapies for inflammatory diseases.

Tocilizumab (Anti-Human IL6R) is a neutralizing antibody against human interleukin-6 receptor (IL-6R) that blocks the binding of IL-6 to IL-6R.Cost-effective and quality-assured.

<p>Tocilizumab is an immunosuppressive agent used in the treatment of rheumatoid arthritis. Chemically, tocilizumab is a monoclonal antibody that interferes with the binding of interleukin-6 (IL-6) to its receptor (IL-6R). Tocilizumab has been positively applied to the treatment of COVID-19 patients.</p>

CAS 375823-41-9

Tocilizumab

Tocilizumab

Ref: TM-T9911

Tocilizumab - 20 mg/ml in PBS

Ref: 3D-BT165595